This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

22 Sep 2011

KAI Signs Deal with Ono to Develop KAI-4169

Under the agreement, Ono will receives exclusive rights to all indications for injectable formulations of KAI-4169 in Japan, while KAI retains marketing rights in all other regions of the world.

KAI Pharmaceuticals, a privately held drug discovery and development company, has signed an agreement with Japan's Ono Pharmaceutical for the development and commercialisation of KAI-4169 in Japan.


KAI-4169, an intravenous formulation for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease-mineral and bone disorder is currently in Phase II clinical testing.


PhaseI1 data demonstrated that single intravenous doses of KAI-4169 were safe and well-tolerated, and resulted in sustained reductions in serum levels of parathyroid hormone in both healthy male subjects and end-stage renal disease patients with secondary hyperparathyroidism.


Under the agreement, Ono will receive

Related News